Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
| ▸ | PDE9A | O76083 | 2/20 | 0.46 |
| ▸ | RIOK2 | Q9BVS4 | 3/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 3/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3582536 | 0.99 | PDE5A (0.45) | PDE5APDE9ARIOK2JUNNFKB1 | |
| SCHEMBL11997252 | 0.99 | PDE5A (0.45) | PDE5APDE9ARIOK2JUNNFKB1 | |
| SCHEMBL3592830 | 0.91 | PDE9A (0.56) | PDE5APDE9AJUNNFKB1NFKB2 | |
| SCHEMBL3593030 | 0.90 | PDE9A (0.44) | PDE5APDE9ARIOK2JUNNFKB1 | |
| SCHEMBL3591537 | 0.90 | PDE9A (0.55) | PDE5APDE9AJUNNFKB1NFKB2 | |
| SCHEMBL11997250 | 0.90 | PDE9A (0.55) | PDE5APDE9AJUNNFKB1NFKB2 | |
| SCHEMBL3599063 | 0.82 | PDE5A (0.47) | PDE5APDE9ARIOK2JUNNFKB1 | |
| SCHEMBL3593857 | 0.81 | PDE5A (0.53) | PDE5APDE9AJUNNFKB1NFKB2 | |
| SCHEMBL3586839 | 0.78 | KDM4E (0.38) | PDE5APDE9ARIOK2PDE2AKDM4E | |
| SCHEMBL3597364 | 0.78 | PDE9A (0.40) | PDE5APDE9ARIOK2PDE2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| EP-2848620-A1 | Quinoxaline derivatives | ASKA Pharmaceutical Co., Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| EP-2848620-A1 | Quinoxaline derivatives | ASKA Pharmaceutical Co., Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | ASKA PHARM CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | ASKA PHARM CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8829000-B2 | Substituted imidazo[1,5-A]quinoxalines as phosphodiesterase 9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829000-B2 | Substituted imidazo[1,5-A]quinoxalines as phosphodiesterase 9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20130225572-A1 | Substituted Imidazo[1,5-A]Quinoxalines As a PDE9 Inhibitor | OKADA MAKOTO (JP) | 2013-08-29 | — | — | US | disclosed |
| US-8299080-B2 | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299080-B2 | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299080-B2 | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2489667-A1 | Quinoxaline derivative | ASKA Pharmaceutical Co., Ltd. (JP) | 2012-08-22 | — | — | EP | disclosed |
| EP-2489667-A1 | Quinoxaline derivative | ASKA Pharmaceutical Co., Ltd. (JP) | 2012-08-22 | — | — | EP | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2103613-A1 | QUINOXALINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-2103613-A1 | QUINOXALINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225572-A1 | Substituted Imidazo[1,5-A]Quinoxalines As a PDE9 Inhibitor | PDE9A, ADCY9, PDE3A | PDE5A 6/4885PDE9A 1/4885RIOK2 861/4885 |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | PDE9A, ADCY9, PRMT9 | PDE5A 8/4885PDE9A 1/4885RIOK2 815/4885 |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | PDE9A, ADCY9, PDE3A | PDE5A 6/4885PDE9A 1/4885RIOK2 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.